Added to YB: 2026-03-30
Pitch date: 2026-03-25
CNTB [bullish]
Connect Biopharma Holdings Limited
+1.47%
current return
Author Info
No bio for this author
Company Info
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.
Market Cap
$187.8M
Pitch Price
$3.40
Price Target
6.72 (+95%)
Dividend
N/A
EV/EBITDA
-2.45
P/E
-3.78
EV/Sales
175.64
Sector
Biotechnology
Category
special_situation
A free option on a new standard of care respiratory biologic. - Connect Biopharma Holdings Limited
CNTB: Single-asset microcap ($175M MC) with Rademikibart (IL4-alpha blocker). Pivotal Chinese AD trial results 3/28/26 at AAD; NDA submitted. Simcere paid $26M upfront, funding phase 3; licensing likely by year-end. 20% China AD share, 10% royalty = ~$200M NPV + $20-30M milestones vs $120M EV = probable double. Free lotto: phase 1b IV study readout in 2 weeks testing acute asthma/COPD use in ED (24hr FEV1 benefit vs dupilumab's 2wks). 3M US ED visits, 30% elevated eosinophils, $450-650M addressable at $700/infusion. Market assigns zero value to acute respiratory story; POC by summer. 50% success odds on binary, 90%+ on China license post-AAD.
Read full article (5 min)